• VIDAS® Hepatitis panel

VIDAS® Hepatitis panel

Routine and confirmation testing of Hepatitis A, B and C

The VIDAS® Hepatitis panel includes 9 markers for diagnosis of recent infection, monitoring of chronic hepatitis, pre- or post-vaccination immunity controls and screening during pregnancy.

  • Comprehensive panel for the differential diagnosis of hepatitis
  • Rapid, simple and reliable testing in less than 2 hours
  • Flexible and cost-effective solution
Add to my selection

Do you need more information

Viral hepatitis affects over 500 million people worldwide. With prevalence higher than that of HIV or cancer, it represents one of the major global health problems. Diagnosis is key as hepatitis infections are “silent” and the majority of those infected are unaware.

The VIDAS® Hepatitis panel includes 9 automated assays offering a complete solution for the diagnosis and monitoring of Hepatitis A, B and C. Used together, they enable clinicians to provide a differential diagnosis for patients presenting with symptoms suggestive of hepatitis.
 

A complete panel to address a complex clinical picture

Hepatitis, especially hepatitis B, presents a complex clinical picture. Various markers are necessary for accurate diagnosis and efficient monitoring:


Hepatitis B infection kinetics

 


Hepatitis A infection kinetics

 


Hepatitis C infection kinetics

 

The VIDAS® Hepatitis assays provide answers to different clinical situations:

  • Screening and diagnosis of recent infection: HAV IgM, HBs Ag Ultra, HBc IgM II, Anti-HCV
  • Monitoring of chronic hepatitis: HBs Ag Ultra, HBe/Anti-HBe, Anti-HBs Total II
  • Pre- or post-vaccination immunity controls: Anti-HAV Total, Anti-HBs Total II, Anti-HBc Total II
  • Screening during pregnancy: HBs Ag Ultra, Anti-HCV
     

Solution benefits

Easy to perform:

  • Automated assays
  • Load and Go

Cost-effective:

  • Single-dose tests
  • Convenient kit size: 30 or 60 tests
  • All-inclusive kits
  • Limited calibration

Reliable:

  • The performance of each marker has been verified by reference laboratories
  • No cross-contamination
  • Robust system: MTBF>700 days
     

Expertise in Infectious Diseases

The history of bioMérieux is directly linked to the fight against infectious diseases, which has been our priority for 50 years. Our research teams constantly focus on pushing back the frontiers of disease detection by dedicating the majority of their activities to the prevention and diagnosis of infection risk.

bioMérieux provides tests for the early detection of numerous diseases, including HIV/AIDS, hepatitis, tuberculosis, respiratory infections, CNS infections, sepsis, C. difficile

Parameter

 Reference 

 Tests/kit 

Sample type

Sample volume

Time to result (minutes)

Calibration frequency

Hepatitis A

VIDAS® HAV IgM 30307 30 Serum, plasma (EDTA, Hep.) 100 µl 60 14 days
VIDAS® Anti-HAV Total 30312 30 Serum, plasma (Hep., EDTA, Cit.) 150 µl 90 14 days

Hepatitis B

VIDAS® HBs Ag Ultra 30315 60 Serum, plasma (EDTA, Hep.) 150 µl 60(HBS)
90(HBL)
14 days
VIDAS® HBs Ag Ultra Confirmation 30317 30       14 days
VIDAS® Anti-HBs Total II 30318 60 Serum, plasma (Hep., EDTA, Cit.) 200 µl 60 28 days
VIDAS® Anti-HBc Total II 30314 60 Serum, plasma (Hep., EDTA, Cit.) 150 µl 90 14 days
VIDAS® HBc IgM II 30439 30 Serum, plasma (Hep., EDTA, Cit.) 100 µl 55 14 days
VIDAS® HBe/Anti-HBe 30305 30 Serum, plasma (Hep., EDTA, Cit.) 150 µl 90 14 days

Hepatitis C

VIDAS® Anti-HCV 30308 60 Serum, plasma (Hep.) 100 µl 40 28 days

 

Find more technical details on www.myvidas.com.

Consult your local bioMérieux representative for product availability in your country.

Related Publications

  • Salvetti S, Lavinia F, Montenora I, Performance del kit per la determinazione di anticorpi anti-HCV sul sistema automatizzato VIDAS, Associazione Microbiologi Clinici Italiani (AMCLI) 2013, November 12-15, Rimini, Italy
  • Servant-Delmas A, Mercier-Darty M, Duong Ly T, Wind F, Alloui C, Sureau C, Laperche S, Variable capacity of 13 hepatitis B virus surface antigen assays for the detection of HBsAg mutants in blood samples, Journal of Clinical Virology, 53 (2012) 338– 345
  • Seigneres B, Ripoll N, Mercier L, Forge F, Prétis C, Baron-Wunderle V, Dugua JM, Performance evaluation of VIDAS® Anti-HCV, a new automated immunoassay test for the qualitative detection of antibodies anti-HCV in human serum and plasma samples, ECCMID 2012, March 31-April 3, London, United Kingdom
  • Seignères B, Ripoll N, Mercier L, Forge F, Prétis C, Riou B, Dugua JM, Avellon AM, Echevarria JM, Hausmann M, Sensitivity and specificity evaluation of a new automated immunoassay test, VIDAS® Anti-HCV, for the qualitative detection of antibodies anti-HCV in human samples, ISVHLD 2012, June 22-25, Shanghai, China

Useful Links

 

Find more scientific and educational resources on www.myvidas.com.

Pioneering diagnostics